Department of Dermatology, Seoul National University College of Medicine, Seoul, Korea.
J Eur Acad Dermatol Venereol. 2013 Apr;27(4):494-8. doi: 10.1111/j.1468-3083.2012.04471.x. Epub 2012 Feb 20.
Assessment of minimal erythemal dose (MED) for individual patients has been used to guide the narrowband Ultraviolet B (NB-UVB) phototherapy, which sometimes causes discomfort and additional time. The L* value (the lightness of color in Commission Internationlale de l'Eclairge Lab* color scale) measured by colorimeter was shown to be useful for predicting sensitivity to NB-UVB irradiation.
To compare the efficacy and safety of NB-UVB phototherapy between 50% of MED and colorimetric L* value starting dose regimens for skin phototype III-V Korean patients with psoriasis.
Twenty seven patients determined starting doses based on colorimetric L* value, and 27 patients based on 50% of MED. Since correlation analysis showed that L* value had the most significant association with MED compared with skin phototypes, a*, and b* values, we designated starting doses of L* value regimen as follows: 300 mJ/cm(2) (L* >66), 400 mJ/cm(2) (62 < L* ≤ 66), and 500 mJ/cm(2) (L* ≤ 62).
There was no significant difference between two groups in clinical efficacy including response rate, mean number of sessions, duration of treatment, maximum dose and cumulative dose until achieving the state of near clearance. The proportion of adverse effects was not also significantly different.
NB-UVB starting dose determination based on colorimetric L* value was comparable with conventional MED based regimen in efficacy and safety for skin phototype III-V patients. Since it provides much convenience and ease for both patients and physicians, colorimetric L* value could partly substitute the MED checking methods in NB-UVB phototherapy.
评估最小红斑量(MED)对于指导窄谱中波紫外线(NB-UVB)光疗非常重要,但是这种方法有时会导致患者不适并增加治疗时间。比色计测量的 L值(CIE Lab颜色空间中的颜色亮度)已被证明可用于预测对 NB-UVB 照射的敏感性。
比较基于 MED 和比色 L*值起始剂量的 NB-UVB 光疗在韩国 III-V 型皮肤银屑病患者中的疗效和安全性。
27 例患者根据比色 L值确定起始剂量,27 例患者根据 MED 的 50%确定起始剂量。由于相关性分析显示,与皮肤光型、a值和 b值相比,L值与 MED 相关性最强,因此我们将 L值方案的起始剂量指定为:300 mJ/cm(2)(L >66)、400 mJ/cm(2)(62 < L* ≤ 66)和 500 mJ/cm(2)(L* ≤ 62)。
两组在临床疗效(包括缓解率、平均治疗次数、治疗持续时间、最大剂量和累积剂量直至达到接近清除状态)方面无显著差异。不良反应的比例也无显著差异。
基于比色 L值的 NB-UVB 起始剂量确定与传统 MED 方案在 III-V 型皮肤患者中的疗效和安全性相当。由于它为患者和医生提供了极大的便利和舒适,比色 L值可以部分替代 NB-UVB 光疗中的 MED 检查方法。